Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors
- PMID: 11074211
- DOI: 10.1016/s0002-9149(00)01171-1
Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors
Erratum in
- Am J Cardiol 2001 May 1;87(9):1138
Abstract
The purpose of this study was to determine if long-term use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (atorvastatin, fluvastatin, lovastatin, pravastatin, or simvastatin) resulted in tachyphylaxis (a decreasing response to a physiologically active agent). To determine this, the charts of 254 patients treated with statins from the years 1996 to 1998 were retrospectively reviewed. During treatment, the low-density lipoprotein (LDL) cholesterol levels of patients were followed for a minimum of 300 days. To characterize LDL cholesterol changes during statin therapy, linear and nonlinear kinetic models were generated. Tachyphylaxis, defined as a positive slope of LDL cholesterol over time, after maximum LDL cholesterol reduction, was identified in patients treated with atorvastatin at exposure doses of 10 or 20 mg/day. All other statins, at all doses reviewed, showed no [corrected] evidence of tachyphylaxis. LDL cholesterol tachyphylaxis appeared to be a unique response to prolonged use of long half-life atorvastatin therapy at exposure dosages.
Comment in
-
Tachyphylaxis and statin drugs.Am J Cardiol. 2001 Mar 1;87(5):674. doi: 10.1016/s0002-9149(01)01456-4. Am J Cardiol. 2001. PMID: 11245286 No abstract available.
-
Tachyphylaxis in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.Am J Cardiol. 2001 Apr 15;87(8):1032-4. doi: 10.1016/s0002-9149(01)01543-0. Am J Cardiol. 2001. PMID: 11327075 No abstract available.
-
Development of tachyphylaxis on statin treatment.Am J Cardiol. 2001 Oct 15;88(8):936-7. Am J Cardiol. 2001. PMID: 11676971 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
